Introduction Biliary cast syndrome (BCS) is an uncommon but clinically significant biliary complication after liver transplantation, characterized by the formation of obstructive biliary debris within the graft biliary tree. It has traditionally been associated with ischemic biliary injury, biliary strictures, and hepatic artery compromise, and may contribute to recurrent cholangitis, graft dysfunction, and, in severe cases, graft loss.
Introduction
Biliary cast syndrome (BCS) is an uncommon but clinically significant biliary complication after liver transplantation, characterized by the formation of obstructive biliary debris within the graft biliary tree. It has traditionally been associated with ischemic biliary injury, biliary strictures, and hepatic artery compromise, and may contribute to recurrent cholangitis, graft dysfunction, and, in severe cases, graft loss. However, contemporary data defining its risk profile—particularly across living donor and deceased donor liver transplantation—remain limited.
Problem Statement
The determinants of BCS after liver transplantation are incompletely understood, especially whether the risk differs meaningfully between living donor liver transplantation (LDLT) and deceased donor liver transplantation (DDLT). This distinction is clinically important because donor type influences ischemic exposure, biliary vulnerability, and postoperative management. Clarifying the major predictors of BCS and its long-term clinical impact may improve surveillance strategies and guide early intervention.
Summary
In this single-center retrospective study of 469 adult liver transplant recipients, BCS developed in 6.6% of patients. The risk was markedly higher after DDLT than LDLT, identifying deceased donor grafts as the strongest independent predictor of BCS. Additional major risk factors included biliary stricture, hepatic arterial complications, and older donor age, reinforcing the central role of ischemic and biliary injury in BCS pathogenesis. Despite its clinical relevance, BCS did not adversely affect long-term graft or overall survival when managed appropriately. Endoscopic intervention appeared effective in controlling disease progression and preserving outcomes, even in patients with established BCS. These findings highlight DDLT recipients as a higher-risk population requiring closer biliary surveillance and support early endoscopic management as a key strategy to maintain favorable long-term transplant outcomes.
Introduction: Bacterial infections remain a major cause of morbidity after liver transplantation despite advances in perioperative care. Synbiotics, combining probiotics and prebiotics, have been proposed to reduce postoperative infections by restoring gut microbiota and strengthening...
Introduction: Perioperative bleeding remains a major challenge during orthotopic liver transplantation (OLT), largely due to hyperfibrinolysis and coagulation abnormalities. Although tranexamic acid (TXA) effectively reduces bleeding in several surgical settings, its routine prophylactic use during...
Introduction: Liver transplantation is limited by a shortage of suitable donor organs. Current viability assessment relies on needle biopsy, which samples only a small portion of the liver and may miss important regional pathology. This...
Introduction: Bleeding remains a major challenge during liver transplantation despite advances in surgical techniques, anesthesia, and perioperative care. Antifibrinolytic agents have long been used to reduce intraoperative blood loss and transfusion requirements. However, evolving transplant...
Introduction: The demand for liver transplantation continues to exceed the availability of deceased donor organs, resulting in prolonged waiting times and preventable waitlist mortality. This perspective discusses how living donor liver transplantation (LDLT) can complement...
Introduction: Pediatric liver transplantation has achieved excellent survival rates, shifting the focus from graft survival alone to optimising long-term health, growth, neurodevelopment, and quality of life. This updated guideline provides evidence-based recommendations for comprehensive care...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.